Triple

T22457829
Position Surface form Disambiguated ID Type / Status
Subject ICH E2C(R2) E555158 entity
Predicate fullName P16 FINISHED
Object Periodic Benefit-Risk Evaluation Report (PBRER) NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Periodic Benefit-Risk Evaluation Report (PBRER) | Statement: [ICH E2C(R2), fullName, Periodic Benefit-Risk Evaluation Report (PBRER)]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Periodic Benefit-Risk Evaluation Report (PBRER)
Context triple: [ICH E2C(R2), fullName, Periodic Benefit-Risk Evaluation Report (PBRER)]
  • A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • B. FDA Risk Evaluation and Mitigation Strategies authority
    The FDA Risk Evaluation and Mitigation Strategies authority is the U.S. Food and Drug Administration’s power to require special safety measures and monitoring programs for certain high-risk prescription drugs to ensure their benefits outweigh their risks.
  • C. Pharmacovigilance Risk Assessment Committee
    The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
  • D. FDA Adverse Event Reporting System
    The FDA Adverse Event Reporting System is a U.S. Food and Drug Administration database that collects and analyzes reports of adverse events and medication errors associated with drugs and therapeutic biologic products.
  • E. Behavioral Risk Factor Surveillance System
    The Behavioral Risk Factor Surveillance System is a large, ongoing U.S. health-related telephone survey system that collects data on health behaviors, chronic conditions, and preventive service use among adults.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Periodic Benefit-Risk Evaluation Report (PBRER)
Target entity description: The Periodic Benefit-Risk Evaluation Report (PBRER) is a standardized pharmacovigilance document used by pharmaceutical companies to periodically assess and summarize the evolving benefits and risks of a medicinal product throughout its lifecycle.
  • A. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • B. FDA Risk Evaluation and Mitigation Strategies authority
    The FDA Risk Evaluation and Mitigation Strategies authority is the U.S. Food and Drug Administration’s power to require special safety measures and monitoring programs for certain high-risk prescription drugs to ensure their benefits outweigh their risks.
  • C. Pharmacovigilance Risk Assessment Committee
    The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
  • D. FDA Adverse Event Reporting System
    The FDA Adverse Event Reporting System is a U.S. Food and Drug Administration database that collects and analyzes reports of adverse events and medication errors associated with drugs and therapeutic biologic products.
  • E. Behavioral Risk Factor Surveillance System
    The Behavioral Risk Factor Surveillance System is a large, ongoing U.S. health-related telephone survey system that collects data on health behaviors, chronic conditions, and preventive service use among adults.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e11e51fdec8190adfdf9f8a6362221 completed April 16, 2026, 5:37 p.m.
NER Named-entity recognition batch_69f15b7d00208190955a70e2c22d25a4 completed April 29, 2026, 1:14 a.m.
Created at: April 16, 2026, 8:48 p.m.